Imetelstat in patients with lower-risk myelodysplastic syndromes who ... - The Lancet
BYSI Stock | USD 1.64 0.07 4.09% |
Under 54% of BeyondSpring's investor base is interested to short. The analysis of the overall investor sentiment regarding BeyondSpring suggests that many traders are impartial. BeyondSpring's investing sentiment shows overall attitude of investors towards BeyondSpring.
BeyondSpring |
Imetelstat in patients with lower-risk myelodysplastic syndromes who ... The Lancet
Read at news.google.com
BeyondSpring Investor Sentiment by Other News Outlets
Investor sentiment, mood or attitude towards BeyondSpring can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
BeyondSpring Fundamental Analysis
We analyze BeyondSpring's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of BeyondSpring using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of BeyondSpring based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Shares Owned By Insiders
Shares Owned By Insiders Comparative Analysis
BeyondSpring is currently under evaluation in shares owned by insiders category among its peers. Shares Owned by Insiders show the percentage of outstanding shares owned by insiders (such as principal officers or members of the board of directors) or private individuals and entities with over 5% of the total shares outstanding. Company executives or private individuals with access to insider information share information about a firm's operations that is not available to the general public.
BeyondSpring Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with BeyondSpring stock to make a market-neutral strategy. Peer analysis of BeyondSpring could also be used in its relative valuation, which is a method of valuing BeyondSpring by comparing valuation metrics with similar companies.
Peers
BeyondSpring Related Equities
ARMP | Armata Pharmaceuticals | 4.29 | ||||
ADTX | Aditxt | 2.94 | ||||
MCRB | Seres Therapeutics | 2.33 | ||||
SRZN | Surrozen | 1.44 | ||||
SLS | Sellas Life | 1.16 | ||||
FBRX | Forte Biosciences | 0.52 | ||||
KTTA | Pasithea Therapeutics | 0.75 | ||||
INKT | Mink Therapeutics | 1.59 | ||||
PLX | Protalix Biotherapeutics | 1.64 | ||||
ALVR | Allovir | 2.17 | ||||
MIST | Milestone Pharmaceuticals | 3.23 | ||||
ONCY | Oncolytics Biotech | 3.57 | ||||
SCPH | Scpharmaceuticals | 3.63 | ||||
RVPH | Reviva Pharmaceuticals | 5.78 | ||||
EYPT | Eyepoint Pharmaceuticals | 6.05 | ||||
CADL | Candel Therapeutics | 31.12 |
Complementary Tools for BeyondSpring Stock analysis
When running BeyondSpring's price analysis, check to measure BeyondSpring's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy BeyondSpring is operating at the current time. Most of BeyondSpring's value examination focuses on studying past and present price action to predict the probability of BeyondSpring's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move BeyondSpring's price. Additionally, you may evaluate how the addition of BeyondSpring to your portfolios can decrease your overall portfolio volatility.
AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
Bonds Directory Find actively traded corporate debentures issued by US companies | |
Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
Fundamental Analysis View fundamental data based on most recent published financial statements | |
Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
FinTech Suite Use AI to screen and filter profitable investment opportunities | |
My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like |